A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) […]
Biosimilar Competition Does Not Reduce Patient Out-of-Pocket Costs for Biologic Drugs Read Post »
A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the
Unleashing Innovation: The Case for Permissionless R&D in Pharma Read Post »
LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This
LACTOSE-Free Medicines: Which Drugs Contain LACTOSE? Read Post »
GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This
GELATIN-Free Medicines: Which Drugs Contain GELATIN? Read Post »
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market
Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma Read Post »
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking
Drug Excipient Business Development Reports now Available on Amazon Read Post »
The recent paper published in PLOS ONE presents a novel approach for efficiently retrieving a substantial number of patents related
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper
Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book Read Post »
A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed
An AI Approach to Generate Novel Pharmaceuticals using Patent Data Read Post »
Get fresh news and insights, drug patent expirations & more…
